Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a ...

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief Scientific Officer, Dr. Victor ...

Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was ...

Commissioners visit UD-based NIIMBL, where public-private partnerships promote innovation, workforce development ...

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Therapeutics announced the presentation of a poster containing data on a new DRP, Drug Response Predictor, for the monoclonal ...

Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury Indications. TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: N ...

Transgene Provides Business and Financial Update for Q1 2025  TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025Dr. Simone Steiner appointed Chief ...

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin ...